First-pass metabolism via UDP-glucuronosyltransferase: A barrier to oral bioavailability of phenolics

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3655-3681

  Wu, Baojian ^a   Kulkarni, Kaustubh ^a   Basu, Sumit ^a   Zhang, Shuxing ^b   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bioavailability; First pass metabolism; Flavonoids; Glucuronidation; Phenolics; Polyphenols; Regioselectivity; UGTs

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRAQUINONE; CATECHIN; CHALCONE DERIVATIVE; CODEINE; COUMARIN DERIVATIVE; DAIDZEIN; EMODIN; ENTACAPONE; EZETIMIBE; FENRETINIDE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOL; FLAVOPIRIDOL; GENISTEIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B; IRINOTECAN; ISOFLAVONE DERIVATIVE; MORPHINE; MYCOPHENOLIC ACID; PARACETAMOL; PHENOL DERIVATIVE; PHENYLEPHRINE; STILBENE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY SPECIFICITY; BREAST CANCER; CATALYSIS; CHRONIC PAIN; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; FIRST PASS EFFECT; HUMAN; INTESTINE; LIVER METABOLISM; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SEX DIFFERENCE; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 79960147010     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22568     Document Type: Review

References (214)

1. Birt DF, Hendrich S, Wang W. 2001. Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Ther 90(2-3):157-177.
2. Ross JA, Kasum CM. 2002. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19-34.
3. Crozier A, Jaganath IB, Clifford MN. 2009. Dietary phenolics: Chemistry, bioavailability and effects on health. Nat Prod Rep 26(8):1001-1043.
4. Hu M. 2007. Commentary: Bioavailability of flavonoids and polyphenols: Call to arms. Mol Pharm 4(6):803-806.
5. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. 2001. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131(4):1362S-1375S.
6. Gao S, Hu M. 2010. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 10(6):550-567.
7. Jeong EJ, Liu X, Jia X, Chen J, Hu M. 2005. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Curr Drug Metab 6(5):455-468.
8. Liu Z, Hu M. 2007. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 3(3):389-406.
9. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. 2010. Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11(8):678-685
10. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
11. Ritter JK. 2000. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129(1-2):171-193.
12. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. 2005. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44(5):467-494.
13. Zhang Y, Song TT, Cunnick JE, Murphy PA, Hendrich S. 1999. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr 129(2):399-405.
14. Zhang L, Zuo Z, Lin G. 2007. Intestinal and hepatic glucuronidation of flavonoids. Mol Pharm 4(6):833-845.
15. Ehrhardt C, Kim K. 2008. Drug absorption studies: In situ, in vitro and in silico models. AAPS press.
16. Miners JO, Mackenzie PI, Knights KM. 2010. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42(1):189-201.
17. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. 2005Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenetics Genomics 15:677-685.
18. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. 2001. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33(3-4):273-297.
19. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. 2008. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36(8):1461-1464.
20. Ohno S, Nakajin S. 2009. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37(1):32-40.
21. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, Yokoi T. 2009. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37(8):1759-1768.
22. Owens IS, Basu NK, Banerjee R. 2005. UDP-glucuronosyltransferases: Gene structures of UGT1 and UGT2 families. Methods Enzymol 400:1-22.
23. Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. 2003. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31(3):326-333.
24. Buckley DB, Klaassen CD. 2007. Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35(1):121-127.
25. Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P. 2010. Sex Differences in UDP-Glucuronosyltransferase 2B17 Expression and Activity. Drug Metab Dispos 38(12):2204-2209.
26. Magdalou J, Fournel-Gigleux S, Ouzzine M. 2010. Insights on membrane topology and structure/function of UDP-glucuronosyltransferases. Drug Metab Rev 42(1):154-161.
27. Kobayashi T, Sleeman JE, Coughtrie MWH, Burchell B. 2005. Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family. Biochem J 400:281-289.
28. Bossuyt X, Blanckaert N. 1995. Mechanism of stimulation of microsomal UDP-glucurosyltransferase by UDP-N-acetylglucosamine. Biochem J 305:321-328.
29. Zakim D, Dannenberg AJ. 1992. How does the microsomal membrane regulate UDP-glucuronosyltransferases? Biochem Pharmacol 43(7):1385-1393.
30. Csala M, Staines AG, Banhegyi G, Mandl J, Coughtrie MWH, Burchell B. 2004. Evidence for multiple glucuronide transporters in rat liver microsomes. Biochem Pharmacol 68:1353-1362.
31. Finel M, Kurkela M. 2008. The UDP-glucuronosyltransferases as oligomeric enzymes. Curr Drug Metab 9:70-76.
32. Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, Magdalou J. 2005. Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol 400:116-147.
33. Bock KW, Köhle C. 2009. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: Advances and open questions. Biochem Pharmacol 77(9):1458-1465.
34. Bowles D, Lim EK, Poppenberger B, Vaistij FE. 2006. Glycosyltransferases of lipophilic small molecules. Annu Rev Plant Biol 57:567-597.
35. Paquette S, Moller BL, Bak S. 2003. On the origin of family 1 plant glycosyltransferases. Phytochemistry 62:399-413.
36. Ross J, Li Y, Lim E, Bowles DJ. 2001. Higher plant glycosyltransferases. Genome Biol 2(2):REVIEWS3004.
37. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR. 2007. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369(2):498-511.
38. Shao H, He X, Achnine L, Blount JW, Dixon RA, Wang X. 2005. Crystal structures of a multifunctional triterpene/flavonoid glycosyltransferase from Medicago truncatula. Plant Cell 17:3141-3154.
39. Offen W, Martinez-Fleites C, Yang M, Kiat-Lim E, Davis BG, Tarling CA, Ford CM, Bowles DJ, Davies GJ. 2006. Structure of a flavonoid glucosyltransferase reveals the basis for plant natural product modification. EMBO J 25:1396-1405.
40. Li L, Modolo LV, Escamilla-Trevino, LL, Achnine L, Dixon RA, Wang X. 2007. Crystal structure of Medicago truncatula UGT85H2-Insights into the structural basis of a multifunctional (Iso)flavonoid glycosyltransferase. J Mol Biol 370:951-963.
41. Brazier-Hicks M, Offen WA, Gershater MC, Revett TJ, Lim EK, Bowles DJ, Davies GJ, Edwards R. 2007. Characterization and engineering of the bifunctional N- and O-glucosyltransferase involved in xenobiotic metabolism in plants. Proc Natl Acad Sci 104:20238-20243.
42. Modolo LV, Li L, Pan H, Blount JW, Dixon RA, Wang X. 2009. Crystal structures of glycosyltransferase UGT78G1 reveal the molecular basis for glycosylation and deglycosylation of (iso)flavonoids. J Mol Biol 392(5):1292-1302.
43. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. 1999. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31: 817-899.
44. Radominska-Pandya A, Bratton SM, Redinbo MR, Miley MJ. 2010. The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: The significance for human UGTs from both the 1A and 2B families. Drug Metab Rev 42(1):128-139.
45. Itäaho K, Laakkonen L, Finel M. 2010. How many and which amino acids are responsible for the large activity differences between the highly homologous UDP-glucuronosyltransferases (UGT) 1A9 and UGT1A10? Drug Metab Dispos 38(4):687-696.
46. Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A. 2006. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry 45(7):2322-2332.
47. Starlard-Davenport A, Xiong Y, Bratton S, Gallus-Zawada A, Finel M, Radominska-Pandya A. 2007. Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10. Steroids 72(1):85-94.
48. Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M. 2007. Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33. FEBS J 274(5):1256-1264.
49. Li C, Wu Q. 2007. Adaptive evolution of multiple-variable exons and structural diversity of drug metabolizing enzymes. BMC Evol Biol 7:69.
50. Locuson CW, Tracy TS. 2007. Comparative modelling of the human UDPglucuronosyltransferases: Insights into structure and mechanism. Xenobiotica 37(2):155-168.
51. Laakkonen L, Finel M. 2010. A molecular model of the human UGT1A1, its membrane orientation and the interactions between different parts of the enzyme. Mol Pharmacol 77(6):931-939.
52. Fujiwara R, Nakajima M, Yamamoto T, Nagao H, Yokoi T. 2009. In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. Drug Metab Pharmacokinet 24(3):235-244.
53. Osmani SA, Bak S, Møller BL. 2009. Substrate specificity of plant UDP-dependent glycosyltransferases predicted from crystal structures and homology modeling. Phytochemistry 70(3):325-347.
54. Sorich MJ, Smith PA, McKinnon RA, Miners JO. 2002. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12(8):635-645.
55. Wu B, Morrow J, Singh R, Zhang S, Hu M. 2011. 3D-QSAR studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based CoMFA model. J Pharmacol Exp Ther 336(2):403-413.
56. Patana A-S, Kurkela M, Finel M, Goldman A. 2008. Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel 21:537-543.
57. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO. 2009. Influence of N-terminal domain histidine and proline residues on the substrate selectivties of human UDP-glucuronosyltransferase (UGT) 1A1, 1A6, 1A9, 2B7 and 2B10. Drug Metab Dispos 37(9):1948-1955.
58. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M. 2005. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33(7):1017-1026.
59. Zhou J, Tracy TS, Remmel RP. 2010. Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: Evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38(3):431-440.
60. Houston JB, Galetin A. 2005. Modelling atypical CYP3A4 kinetics: Principles and pragmatism. Arch Biochem Biophys 433(2):351-360.
61. Mackenzie PI, Gregory PA, Gardner-Stephen DA, Lewinsky RH, Jorgensen BR, Nishiyama T, Xie W, Radominska-Pandya A. 2003. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 4(3):249-257.
62. Zhou J, Zhang J, Xie W. 2005. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab 6(4):289-298.
63. Bock KW. 2010. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): Mechanisms responsible for interindividual variation of UGT levels. Biochem Pharmacol 80(6):771-777.
64. Basu NK, Kole L, Basu M, Chakraborty K, Mitra PS, Owens IS. 2008. The major chemical-detoxifying system of UDP-glucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J Biol Chem 283(34):23048-23061.
65. Mitra PS, Basu NK, Basu M, Chakraborty S, Saha T, Owens IS. 2011. Regulated phosphorylation of a major UDP-glucuronosyltransferase isozyme by tyrosine kinases dictates endogenous substrate-selection for detoxification. J Biol Chem 286(2):1639-1648.
66. Basu NK, Kole L, Owens IS. 2003. Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303(1):98-104.
67. Basu NK, Korava M, Garza A, Kubota S, Saha T, Mitra PS, Banerjee R, Rivera J, Owens IS. 2005. Phosphorylation of UDP-glucuronosyltransferase regulates substrate specificity. Proc Natl Acad Sci USA 102:6285-6290.
68. Basu NK, Kubota S, Meselhy MR, Ciotti M, Chowdhury B, Hartori M, Owens IS. 2004. Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and non-steroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 279:28320-28329.
69. Mitra PS, Basu NK, Owens IS. 2009. Src supports UDP-glucuronosyltransferase-2B7 detoxification of catechol estrogens associated with breast cancer. Biochem Biophys Res Commun 382(4):651-656.
70. Volak LP, Court MH. 2010. Role for protein kinase C delta in the functional activity of human UGT1A6: Implications for drug-drug interactions between PKC inhibitors and UGT1A6. Xenobiotica 40(5):306-318.
71. Liu Y, Hu M. 2002. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos 30(4):370-377.
72. Chen J, Lin H, Hu M. 2003. Metabolism of flavonoids via enteric recycling: Role of intestinal disposition. J Pharmacol Exp Ther 304(3):1228-1235.
73. Hu M, Chen J, Lin H. 2003. Disposition of flavonoids via recycling: Mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther 307(1):314-321.
74. Ng SP, Wong KY, Zhang L, Zuo Z, Lin G. 2004. Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J Pharm Pharm Sci 8(1):1-9.
75. Liu X, Tam VH, Hu M. 2007. Disposition of flavonoids via enteric recycling: Determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm 4(6):873-882.
76. Cai H, Boocock DJ, Steward WP, Gescher AJ. 2007. Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol 60(2):257-266.
77. Walle UK, Galijatovic A, Walle T. 1999. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58(3):431-438.
78. Galijatovic A, Otake Y, Walle UK, Walle T. 1999. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29(12):1241-1256.
79. Zhang L, Lin G, Zuo Z. 2007. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm Res 24(1):81-89.
80. Xing J, Chen X, Zhong D. 2005. Absorption and enterohepatic circulation of baicalin in rats. Life Sci 78(2):140-146.
81. Akao T, Sakashita Y, Hanada M, Goto H, Shimada Y, Terasawa K. 2004. Enteric excretion of baicalein, a flavone of Scutellariae Radix, via glucuronidation in rat: Involvement of multidrug resistance-associated protein 2. Pharm Res 21(11):2120-2126.
82. Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, Zuo Z. 2007. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur J Pharm Sci 31(3-4):221-231.
83. Sun H, Zhang L, Chow EC, Lin G, Zuo Z, Pang KS. 2008. A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: Demonstration of substrate inhibition. J Pharmacol Exp Ther 326(1):117-126.
84. Zhou Q, Zheng Z, Xia B, Tang L, Lv C, Liu W, Liu Z, Hu M. 2010. Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. Pharm Res 27(8):1568-1583.
85. Tang L, Ye L, Singh R, Wu B, Lv C, Zhao J, Liu Z, Hu M. 2010. Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes. Mol Pharm 7(3):664-679.
86. Boutin JA, Meunier F, Lambert PH, Hennig P, Bertin D, Serkiz B, Volland JP. 1993. In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats. Drug Metab Dispos 21(6):1157-1166.
87. Wang SW, Chen J, Jia X, Tam VH, Hu M. 2006. Disposition of flavonoids via enteric recycling: Structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos 34(11):1837-1848.
88. King RA, Broadbent JL, Head RJ. 1996. Absorption and excretion of the soy isoflavone genistein in rats. J Nutr 126:176-182.
89. King RA, Bursill DB. 1998. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67:867-872.
90. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. 2001. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131 (Suppl 4):1362S-1375S.
91. Chen J, Lin H, Hu M. 2005. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 55(2):159-169.
92. Chen J, Wang S, Jia X, Bajimaya S, Lin H, Tam VH, Hu M. 2005Disposition of flavonoids via recycling: Comparison of intestinal versus hepatic disposition. Drug Metab Dispos 33(12):1777-1784.
93. Zhu W, Xu H, Wang SW, Hu M. 2010. Breast cancer resistance protein (BCRP) and sulfotransferases contributes significantly to the disposition of genistein in mouse intestine. AAPS J 12(4):525-536.
94. Jia X, Chen J, Lin H, Hu M. 2004. Disposition of flavonoids via enteric recycling: Enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther 310(3):1103-1113.
95. Jeong EJ, Jia X, Hu M. 2005. Disposition of formononetin via enteric recycling: Metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol Pharm 2(4):319-328.
96. Otake Y, Hsieh F, Walle T. 2002. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab Dispos 30(5):576-581.
97. Barrington R, Williamson G, Bennett RN, Davis BD, Brodbelt JS, Kroon PA. 2009. Absorption, conjugation and efflux of the flavonoids, kaempferol and galangin, using the intestinal CACO-2/TC7 cell model. J Funct Foods 1(1):74-87.
98. Barve A, Chen C, Hebbar V, Desiderio J, Saw CL, Kong AN. 2009. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos 30(7):356-365.
99. DuPont MS, Day AJ, Bennett RN, Mellon FA, Kroon PA. 2004. Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans. Eur J Clin Nutr 58(6):947-954.
100. Oliveira EJ, Watson DG. 2000. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes. FEBS Lett 471(1):1-6.
101. Williamson G, Barron D, Shimoi K, Terao J. 2005. In vitro biological properties of flavonoid conjugates found in vivo. Free Radic Res 39(5):457-469.
102. Janisch KM, Williamson G, Needs P, Plumb GW. 2004. Properties of quercetin conjugates: Modulation of LDL oxidation and binding to human serum albumin. Free Radic Res 38:877-884.
103. Moon JH, Tsushida T, Nakahara K, Terao J. 2001. Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 30:1274-1285.
104. Wang FM, Yao TW, Zeng S. 2003. Disposition of quercetin and kaempferol in human following an oral administration of Ginkgo biloba extract tablets. Eur J Drug Metab Pharmacokinet 28(3):173-177.
105. Chen YK, Chen SQ, Li X, Zeng S. 2005. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica 35(10-11):943-954.
106. Davis BD, Brodbelt JS. 2008. Regioselectivity of human UDP-glucuronosyl-transferase 1A1 in the synthesis of flavonoid glucuronides determined by metal complexation and tandem mass spectrometry. J Am Soc Mass Spectrom 19(2):246-256.
107. Hsiu SL, Huang TY, Hou YC, Chin DH, Chao PD. 2002. Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci 70(13):1481-1489.
108. Fuhr U, Kummert AL. 1995. The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin Pharmacol Ther 58(4):365-373.
109. Ma Y, Li P, Chen D, Fang T, Li H, Su W. 2006. LC/MS/MS quantitation assay for pharmacokinetics of naringenin and double peaks phenomenon in rats plasma. Int J Pharm 307(2):292-299.
110. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu M. 2009. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6(6):1703-1715.
111. Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Rèmèsy C. 2003. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57:235-242.
112. Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y. 2004. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 52:6653-6659.
113. Brett GM, Hollands W, Needs PW, Teucher B, Dainty JR, Davis BD, Brodbelt JS, Kroon PA. 2009. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br J Nutr 101:664-675.
114. Brand W, van Der Wel PA, Rein MJ, Barron D, Williamson G, van Bladeren PJ, Rietjens IM. 2008. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 36:1794-1802.
115. Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, Meinl W, Glatt H, Williamson G, van Bladeren PJ, Rietjens IM. 2010. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38(4):617-625.
116. Gerhäuser C. 2005. Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41(13):1941-1954.
117. Avula B, Ganzera M, Warnick JE, Feltenstein MW, Sufka KJ, Khan IA. 2004. High-performance liquid chromatographic determination of xanthohumol in rat plasma, urine, and fecal samples. J Chromatogr Sci 42(7):378-382.
118. Yilmazer M, Stevens JF, Buhler DR. 2001. In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. FEBS Lett 491(3):252-256.
119. Ruefer CE, Gerhäuser C, Frank N, Becker H, Kulling SE. 2005. In vitro phase II metabolism of xanthohumol by human UDP-glucuronosyltransferases and sulfotransferases. Mol Nutr Food Res 49(9):851-856.
120. Pang Y, Nikolic D, Zhu D, Chadwick LR, Pauli GF, Farnsworth NR, van Breemen RB. 2007. Binding of the hop (Humulus lupulus L.) chalcone xanthohumol to cytosolic proteins in Caco-2 intestinal epithelial cells. Mol Nutr Food Res 51(7):872-879.
121. Feng WY. 2006. Metabolism of green tea catechins: An overview. Curr Drug Metab 7(7):755-809.
122. Crespy V, Nancoz N, Oliveira M, Hau J, Courtet-Compondu MC, Williamson G. 2004. Glucuronidation of the green tea catechins, (-)-epigallocatechin-3-gallate and (-)-epicatechin-3-gallate, by rat hepatic and intestinal microsomes. Free Radic Res 38(9):1025-1031.
123. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. 2010. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54(1):7-16.
124. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302(1):369-373.
125. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Mérillon JM, Magdalou J, Sabolovic N. 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 393(2):281-289.
126. Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, Green AG, Bradford WW, Green CE, Kapetanovic IM, Iyer LV. 2006. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol 58(4):469-479.
127. Sabolovic N, Humbert AC, Radominska-Pandya A, Magdalou J. 2006. Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27(4):181-189.
128. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C, Hahn U. 2000. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272(1):212-217.
129. Kaldas MI, Walle UK, Walle T. 2003. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 55(3):307-312.
130. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D. 2004. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 68(4):773-782.
131. Roupe K, Teng XW, Fu X, Meadows GG, Davies NM. 2004. Determination of piceatannol in rat serum and liver microsomes: Pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr 18(8):486-491.
132. Miksits M, Maier-Salamon A, Vo TP, Sulyok M, Schuhmacher R, Szekeres T, Jäger W. 2010. Glucuronidation of piceatannol by human liver microsomes: Major role of UGT1A1, UGT1A8 and UGT1A10. J Pharm Pharmacol 62(1):47-54.
133. Delmonte A, Sessa C. 2009. AVE8062: A new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 18(10):1541-1548.
134. Aprile S, Del Grosso E, Grosa G. 2010. Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4. Drug Metab Dispos 38(7):1141-1146.
135. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. 2007. Molecular mechanism of emodin action: Transition from laxative ingredient to an antitumor agent. Med Res Rev 27:591-608.
136. Liang JW, Hsiu SL, Wu PP, Chao PD. 1995. Emodin pharmacokinetics in rabbits. Planta Med 61(5):406-408.
137. Teng ZH, Zhou SY, Yang RT, Liu XY, Liu RW, Yang X, Zhang BL, Yang JY, Cao DY, Mei QB. 2007. Quantitation assay for absorption and first-pass metabolism of emodin in isolated rat small intestine using liquid chromatography-tandem mass spectrometry. Biol Pharm Bull 30(9):1628-1633.
138. Liu W, Tang L, Ye L, Cai Z, Xia B, Zhang J, Hu M, Liu Z. 2010. Species and gender differences affect the metabolism of emodin via glucuronidation. AAPS J 12(3):424-436.
139. Morita K, Sugiyama Y, Hanano M. 1986. Pharmacokinetic study of 4-methylumbelliferone in rats: Influence of dose on its first-pass hepatic elimination. J Pharmacobiody 9(2):117-124.
140. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. 2006. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319(1):459-467.
141. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. 2004. Human udp-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32(4):413-423.
142. Liang SC, Ge GB, Liu HX, Zhang YY, Wang LM, Zhang JW, Yin L, Li W, Fang ZZ, Wu JJ, Li GH, Yang L. 2010. Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab Dispos 38(6):973-980.
143. Issell B, Franke A, Fielding R. 2008. Pharmacokinetic study of noni fruit extract. J Dietary Suppl 5(4):373-382.
144. Jones DR, Moran JH, Miller GP. 2010. Warfarin and UDP-glucuronosyltransferases: Writing a new chapter of metabolism. Drug Metab Rev 42(1):53-539.
145. Prescott LF. 1980. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 10:291S-298S.
146. Xiong H, Turner KC, Ward ES, Jansen PL, Brouwer KL. 2000. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 295(2):512-518.
147. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S. 2006. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol 19(5):701-709.
148. Abid A, Bouchon I, Siest G, Sabolovic N. 1995. Glucuronidation in the Caco-2 human intestinal cell line: Induction of UDP-glucuronosyltransferase 16. Biochem Pharmacol 50:557-561.
149. Siissalo S, Laine L, Tolonen A, Kaukonen AM, Finel M, Hirvonen J. 2010. Caco-2 cell monolayers as a tool to study simultaneous phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol. Int J Pharm 383(1-2):24-29.
150. Stockis A, Deroubaix X, Jeanbaptiste B, Lins R, Allemon AM, Laufen H. 1995. Relative bioavailability of carbinoxamine and phenylephrine from a retard capsule after single and repeated dose adminstration in healthy subjects. Arzneimittelforschung 45(9):1009-1012.
151. Ibrahim KE, Midgley JM, Crowley JR, Williams CM. 1983. The mammalian metabolism of R-(-)-m-synephrine. J Pharm Pharmacol 35(3):144-147.
152. Gumbhir, K. 1993. An investigation of pharmacokinetics of phenylephrine and its metabolites in humans. In Pharmaceutical sciences. University of Missouri-Kansas City, Kansas City, pp 216.
153. Hengstmann, JH, Goronzy J. 1982. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 21:335-341.
154. Wikberg T, Vuorela A, Ottoila P, Taskinen J. 1993. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92.
155. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M. 2005. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33(7):1017-1026.
156. Lautala P, Ethell BT, Taskinen J, Burchell B. 2000. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28(11):1385-1389.
157. Lautala P, Kivimaa M, Salomies H, Elovaara E, Taskinen J. 1997. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. Pharm Res 14(10):1444-1448.
158. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, Obach RS. 2008. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21(12):2260-2271.
159. Jeong EJ, Lin H, Hu M. 2004. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310(1):376-385.
160. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. 2000. Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 56(9-10):659-664.
161. Mackenzie PI. 2000. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22(1):10-13.
162. Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, Zhong MK, Lu WY. 2008. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol 65(6):893-907.
163. Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. 2007The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81(3):392-400.
164. Basu NK, Kole L, Basu M, McDonagh AF, Owens IS. 2007. Targeted inhibition of glucuronidation markedly improves drug efficacy in mice-A model. Biochem Biophys Res Commun 360(1):7-13.
165. Illingworth N, Boddy A, Daly A, Veal G. 2010. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol doi: 10.1111/j.1476-5381.2010.01104.x.
166. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG. 1993. Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst 85(12):993-996.
167. O'Dwyer PJ, Catalano RB. 2006. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534-4538.
168. Fujita K, Sparreboom A. 2010. Pharmacogenetics of irinotecan disposition and toxicity: A review. Curr Clin Pharmacol 5(3):209-217.
169. Beutler E, Gelbart T, Demina A. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
170. Kelland LR. 2000. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin Investig Drugs 9(12):2903-2911.
171. Jäger W, Zembsch B, Wolschann P, Pittenauer E, Senderowicz AM, Sausville EA, Sedlacek HH, Graf J, Thalhammer T. 1998. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 62(20):1861-1873.
172. Innocenti F, Stadler WM, Iyer L, Ramírez J, Vokes EE, Ratain MJ. 2000. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 6(9):3400-3405.
173. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, Senderowicz AM, Sausville EA, Jäger W. 2001. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 29(4):407-414.
174. Ramírez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain MJ, Guillemette C. 2002. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 19(5):588-594.
175. Ramírez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ. 2007. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35(12):2149-2153.
176. Desta Z, Ward BA, Soukhova NV, Flockhart DA. 2004. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062-1075.
177. Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A. 2006. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71(9):1358-1369.
178. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P. 2007. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35(10):1942-1948.
179. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P. 2007. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35(11):2006-2014.
180. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. 2006. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8(4):R50.
181. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P. 2009. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69(5):1892-1900.
182. Joseph TB, Wang SW, Liu X, Kulkarni KH, Wang J, Xu H, Hu M. 2007. Disposition of flavonoids via enteric recycling: Enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. Mol Pharm 4(6):883-894.
183. Jeong EJ, Liu Y, Lin H, Hu M. 2005. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10. Drug Metab Dispos 33(6):785-794.
184. Davis HR, Veltri EP. 2007. Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 14(3):99-108.
185. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32(3):314-320.
186. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129(8):1748-1754.
187. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 102(23):8132-8137.
188. Yamamoto T, Ito K, Honma M, Takada T, Suzuki H. 2007. Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats. Drug Metab Dispos 35(9):1455-1458.
189. Bae JW, Choi CI, Lee JH, Jang CG, Chung MW, Lee SY. 2011 Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur J Clin Pharmacol 67(1):39-45.
190. Chang JH, Yoo P, Lee T, Klopf W, Takao D. 2009. The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe. Mol Pharm 6(4):1216-1227.
191. Kilpatrick GJ, Smith TW. 2005. Morphine-6-glucuronide: Actions and mechanisms. Med Res Rev 25(5):521-544.
192. Joshi GP. 2008. Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain. Curr Opin Investig Drugs 9(7):786-799.
193. van Dorp EL, Morariu A, Dahan A. 2008. Morphine-6-glucuronide: Potency and safety compared with morphine. Expert Opin Pharmacother 9(11):1955-1961.
194. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. 2003. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: Evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31(9):1086-1089.
195. Ohno S, Kawana K, Nakajin S. 2008. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 36(4):688-694.
196. Vree TB, van Dongen RT, Koopman-Kimenai PM. 2000. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Practa 54(6):395-398.
197. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ. 2003. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: Specificity and influence of the UGT2B7 2 polymorphism. Drug Metab Dispos 31(9):1125-1133.
198. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO. 2010. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther 334(2):609-618.
199. Court MH. 2001. Acetaminophen UDP-glucuronosyltransferase in ferrets: Species and gender differences, and sequence analysis of ferret UGT1A6. J Vet Pharmacol Ther 24(6):415-422.
200. Lee JK, Abe K, Bridges AS, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. 2009. Drug Metab Dispos 37(9):1916-1921.
201. Wong YC, Zhang L, Lin G, Zuo Z. 2009. Intestinal first-pass glucuronidation activities of selected dihydroxyflavones. Int J Pharm 366(1-2):14-20.
202. Mizuma T. 2009. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378(1-2):140-141.
203. Wong YC, Zhang L, Lin G, Zuo Z. 2009. Structure-activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. Expert Opin Drug Metab Toxicol 5(11):1399-1419.
204. Zhang L, Lin G, Zuo Z. 2006. Position preference on glucuronidation of mono-hydroxylflavones in human intestine. Life Sci 78(24):2772-2780.
205. Wang SW, Kulkarni KH, Tang L, Wang JR, Yin T, Daidoji T, Yokota H, Hu M. 2009. Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. J Pharmacol Exp Ther 329(3):1023-1031.
206. Shimoi K, Nakayama T. 2005. Glucuronidase deconjugation in inflammation. Methods Enzymol 400:263-272.
207. Lee-Hilz YY, Stolaki M, van Berkel WJ, Aarts JM, Rietjens IM. 2008. Activation of EpRE-mediated gene transcription by quercetin glucuronides depends on their deconjugation. Food Chem Toxicol 46(6):2128-2134.
208. Bohnenstengel F, Kroemer HK, Sperker B. 1999. In vitro cleavage of paracetamol glucuronide by human liver and kidney beta-glucuronidase: Determination of paracetamol by capillary electrophoresis. J Chromatogr B Biomed Sci Appl 721(2):295-299.
209. O'Leary KA, Day AJ, Needs PW, Mellon FA, O'Brien NM, Williamson G. 2003. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: The role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65(3):479-491.
210. Shimoi K, Saka N, Kaji K, Nozawa R, Kinae N. 2000. Metabolic fate of luteolin and its functional activity at focal site. Biofactors 12(1-4):181-186.
211. Shimoi K, Saka N, Nozawa R, Sato M, Amano I, Nakayama T, Kinae N. 2001. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos 29(12):1521-1524.
212. Mochizuki M, Kajiya K, Terao J, Kaji K, Kumazawa S, Nakayama T, Shimoi K. 2004. Effect of quercetin conjugates on vascular permeability and expression of adhesion molecules. Biofactors 22(1-4):201-204.
213. Wen X, Walle T. 2006. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34(10):1786-1792.
214. Patel M, Shah T, Amin A. 2007. Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carrier Syst 24(2):147-202.